Citation Impact
Citing Papers
Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites
2009 StandoutScience
Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis
2010 Standout
Development of a leishmaniasis vaccine: the importance of MPL
2003
Rational Design of Intercellular Adhesion Molecule-1 (ICAM-1) Variants for Antagonizing Integrin Lymphocyte Function-associated Antigen-1-dependent Adhesion
2005 StandoutNobel
Cutaneous Leishmaniasis: Recent Developments in Diagnosis and Management
2015
Functional diversity of helper T lymphocytes
1996 StandoutNature
Recurrent cutaneous leishmaniasis: A role for persistent parasites?
1994
Tumor necrosis factor‐α in combination with interferon‐γ, but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes
1990
Leishmaniasis
2018 Standout
Cutaneous leishmaniasis in the returning traveler
2005
National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications
2012 Standout
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
2007 Standout
Aggravation of experimental cutaneous leishmaniasis in mice by administration of interleukin 3
1988
Randomized, Double-Blind Clinical Trial of Topical Imiquimod 5% with Parenteral Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis in Peru
2005
Leishmaniasis in immunosuppressed individuals
2014
The role of liposomes in clinical nanomedicine development. What now? Now what?
2019 Standout
Can available interventions end preventable deaths in mothers, newborn babies, and stillbirths, and at what cost?
2014 Standout
Role of T cell subsets during the recall of immunologic memory to Leishmania major
1992
Case study for a vaccine against leishmaniasis
2013
Species-Directed Therapy for Leishmaniasis in Returning Travellers: A Comprehensive Guide
2014
The immunology of susceptibility and resistance to Leishmania major in mice
2002 Standout
CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity
2002 StandoutNature
Development and regulation of cell-mediated immunity in experimental Leishmaniasis
2003
Sensitizing Anthrax Lethal Toxin-resistant Macrophages to Lethal Toxin-induced Killing by Tumor Necrosis Factor-α
2003 StandoutNobel
T-Cell Subsets and T-Cell Antigens in Protective Immunity Against Experimental Leishmaniasis
1990
Leishmaniavaccines: progress and problems
2006
Old World Leishmaniasis: An Emerging Infection among Deployed US Military and Civilian Workers
2004
Treatment of cutaneous leishmaniasis among travellers
2004
Epidemiology of Cutaneous Leishmaniasis in Colombia: A Longitudinal Study of the Natural History, Prevalence, and Incidence of Infection and Clinical Manifestations
1993
Protective Reconstitution of the SCID Mouse against Reactivation of Toxoplasmic Encephalitis
1994
Cutaneous leishmaniasis
2007 Standout
Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India
2014
Second-generation vaccines against leishmaniasis
2005
Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran
2004
Natural history, clinical evolution, and the host-parasite interaction in New World cutaneous leishmaniasis
1996
Tick immunity using mRNA, DNA and protein-based Salp14 delivery strategies
2021 StandoutNobel
The Regulation of Immunity to Leishmania Major
1995 Standout
Practical Guide for the Treatment of Leishmaniasis
1998
Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites
2004
The lost hope of elimination of Kala-azar (visceral leishmaniasis) by 2010 and cyclic occurrence of its outbreak in India, blame falls on vector control practices or co-infection with human immunodeficiency virus or therapeutic modalities?
2014
Clinical aspects of visceral leishmaniasis in HIV infection
2012
Virus-induced autoantibody response to a transgenic viral antigen
1990 StandoutNatureNobel
Canine leishmaniasis: novel strategies for control
2002
The epidemiology of visceral leishmaniasis in East Africa: hints and molecular revelations
2002
Leishmaniasis: new approaches to disease control
2003
Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis
2003
The immunology of post-kala-azar dermal leishmaniasis (PKDL)
2016
Vaccines for parasitic and bacterial diseases
2003
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major
2007 Standout
Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)
2002
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
The Cure Rate after Placebo or No Therapy in American Cutaneous Leishmaniasis: A Systematic Review and Meta-Analysis
2016
The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells
2008 StandoutNobel
Stillbirths: the way forward in high-income countries
2011
Recent advances in vaccines for leishmaniasis
2004
Exploring the full spectrum of macrophage activation
2008 Standout
Cutaneous leishmaniasis: immune responses in protection and pathogenesis
2016
Control of Neglected Tropical Diseases
2007 Standout
Liposomal amphotericin B as a treatment for human leishmaniasis
2012
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda
2002
Is Paromomycin an Effective and Safe Treatment against Cutaneous Leishmaniasis? A Meta-Analysis of 14 Randomized Controlled Trials
2009
Leishmaniasis
1999 Standout
The lymphocyte surface. II. Separation of Fc receptor, C'3 receptor and surface immunoglobulin-bearing lymphocytes
1974
LeishMan Recommendations for Treatment of Cutaneous and Mucosal Leishmaniasis in Travelers, 2014
2013
Sequences related to immunoglobulin kappa chain messenger RNA in T cells.
1976 StandoutNobel
In Vitro Approaches to the Mechanism of Cell-Mediated Immune Reactions
1971
Plaque Forming Cells: Methodology and Theory
1974 StandoutNobel
Possible role for the Fc receptor on B lymphocytes
1974 StandoutNatureNobel
Detection of Antigen-Specific T Cells with Multivalent Soluble Class II MHC Covalent Peptide Complexes
1998
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates
2011 StandoutNobel
Roles of protein and carbohydrate in glycoprotein processing and secretion. Studies using mutants expressing altered IgM mu chains.
1981 StandoutNobel
Establishment of Stable, Cell-Mediated Immunity that Makes "Susceptible" Mice Resistant to Leishmania major
1992 Science
IMMUNOLOGICAL TOLERANCE IN BONE MARROW-DERIVED LYMPHOCYTES
1974 StandoutNobel
Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report
2004
Epidemiology of the Leishmaniases
1995
IMMUNOLOGICAL TOLERANCE IN BONE MARROW-DERIVED LYMPHOCYTES
1972 StandoutNobel
Interventions for American cutaneous and mucocutaneous leishmaniasis
2009
Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response
1995
Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis
1994
Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host
1993
Stillbirths: Where? When? Why? How to make the data count?
2011 Standout
CELL SURFACE IMMUNOGLOBULIN
1972
Binding of antigen in the absence of histocompatibility proteins by arsonate-reactive T-cell clones
1984
Functional Specificity of Thymus-Dependent Lymphocytes
1977 StandoutScienceNobel
Activation of cytokine genes in T cells during primary and secondary murine influenza pneumonia.
1993 StandoutNobel
Interventions for Old World cutaneous leishmaniasis
2008
Immune Elimination ofLeishmania majorin Mice: Implications for Immune Memory, Vaccination, and Reactivation Disease
2001
The Potency and Durability of DNA- and Protein-Based Vaccines Against Leishmania major Evaluated Using Low-Dose, Intradermal Challenge
2001
Immunological regulation of experimental cutaneous leishmaniasis. IV. Prophylactic effect of sublethal irradiation as a result of abrogation of suppressor T cell generation in mice genetically susceptible to leishmania tropica
1981
Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: Selective externalization of the receptor
1983 Standout
Advances in leishmaniasis
2005 Standout
A subset of dendritic cells induces CD4+ T cells to produce IFN-γ by an IL-12–independent but CD70-dependent mechanism in vivo
2007 StandoutNobel
Membrane and Cytoplasmic Changes in B Lymphocytes Induced by Ligand-Surface Immunoglobulin Interaction
1976
Differing Lymphokine Profiles of Functional Subsets of Human CD4 and CD8 T Cell Clones
1991 StandoutScience
Mucosal leishmaniasis ("espundia") responsive to low dose of N-methyl glucamine (Glucantime ®) in Rio de Janeiro, Brazil
2000
Effect of Immunological Unresponsiveness on Different Cell Populations
1972
Subpopulations of Mouse Blood Monocytes Differ in Maturation Stage and Inflammatory Response
2004
Membrane Immunoglobulins and Antigen Receptors on B and T Lymphocytes
1974
Single-Step Multiplex PCR Assay for Characterization of New World Leishmania Complexes
1998
In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination
2004 StandoutNobel
Immunological Unresponsiveness
1973
Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease
2002
Tumor necrosis factor alpha (TNF-alpha) and TNF-beta and their receptors in experimental cutaneous leishmaniasis
1994
A RECEPTOR FOR ANTIBODY ON B LYMPHOCYTES
1972
Leishmaniases of the New World: current concepts and implications for future research
1993
Fibroblasts as Host Cells in Latent Leishmaniosis
2000
Immunoglobulin Synthesis and Secretion by Cells in the Mouse Thymus That Do Not Bear θ Antigen
1973
CELL INTERACTIONS IN THE PRIMARY IMMUNE RESPONSE IN VITRO: A REQUIREMENT FOR SPECIFIC CELL CLUSTERS
1969
Immune responses in kala-azar.
2006
Antibodies to major histocompatibility antigens produced by hybrid cell lines
1977 StandoutNatureNobel
GENETIC CONTROL OF THYMUS-DERIVED CELL FUNCTION
1972 StandoutNobel
Clinical features and treatment response of cutaneous leishmaniasis in North‐West Ethiopia
2017
Regulatory T cells: mediating compromises between host and parasite
2002 StandoutNobel
A subset of T cell receptors associated with L3T4 molecules mediates C6VL leukemia cell binding of its cognate retrovirus
1987 StandoutNobel
Leishmaniasis: Current Status of Vaccine Development
2001
Immune Response in vitro: Independence of "Activated" Lymphoid Cells
1969 StandoutScienceNobel
Inhibition of the Spontaneous Apoptosis of Neutrophil Granulocytes by the Intracellular Parasite Leishmania major
2002
Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)
2016
THE PRODUCTION OF MIGRATION INHIBITION FACTOR BY B AND T CELLS OF THE GUINEA PIG
1973 StandoutNobel
The epidemiology and control of leishmaniasis in Andean countries
2000
Vaccination with Phosphoglycan-Deficient Leishmania major Protects Highly Susceptible Mice from Virulent Challenge without Inducing a Strong Th1 Response
2004
Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase.
1996
Vaccination with Heat-killed Leishmania Antigen or Recombinant Leishmanial Protein and CpG Oligodeoxynucleotides Induces Long-Term Memory CD4+and CD8+T Cell Responses and Protection Against Leishmania major Infection
2002
Drug Resistance in Leishmaniasis
2006 Standout
Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection.
1994
The microbial mimic poly IC induces durable and protective CD4+T cell immunity together with a dendritic cell targeted vaccine
2008 StandoutNobel
Is terminal deoxynucleotidyl transferase a somatic mutagen in lymphocytes?
1974 StandoutNatureNobel
Leishmania donovanip36(LACK) DNA Vaccine Is Highly Immunogenic but Not Protective against Experimental Visceral Leishmaniasis
2001
Cysteine Protease B of Leishmania mexicana Inhibits Host Th1 Responses and Protective Immunity
2003
Differences in susceptibility of inbred mice to Bacillus anthracis
1986
Biologic and antigenic similarity of virus-induced migration inhibition factor to conventional, lymphocyte-derived migration inhibition factor.
1975 StandoutNobel
Works of Farrokh Modabber being referenced
Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13–15 June, 2006
2007
Efficacy of Sodium Stibogluconate Alone and in Combination with Allopurinol for Treatment of Mucocutaneous Leishmaniasis
1997
Systemic infection of Leishmania tropica (major) in various strains of mice
1981
Methodology of Clinical Trials Aimed at Assessing Interventions for Cutaneous Leishmaniasis
2013
Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin
1997
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial
2011
First generation leishmaniasis vaccines: A review of field efficacy trials
2008
A model for the mechanism of sensitivity of BALB/c mice to L. major and premunition in leishmaniases
1987
Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia
2005
Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan
2000
Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial
2002
Vaccines against leishmaniasis
1995
Experiences with vaccines against cutaneous leishmaniasis: of men and mice
1989
Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers
2003
Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran
1998
Immunotherapy for Drug‐Refractory Mucosal Leishmaniasis
2006
Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial
2000
Leishmanization: Use of an old method for evaluation of candidate vaccines against leishmaniasis
2005
A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran
1999
Characterization of T and B antigen-binding cells for beta-galactosidase. II. T antigen-binding cells.
1976
Assessment of Interferon-γ Levels and Leishmanin Skin Test Results in Persons Recovered for Leishmaniasis
2012
Effect of cyclophosphamide on Toxoplasma gondii infection: reversal of the effect by passive immunization.
1978
Antigen Binding to Cells: Determination by Enzymic Fluorogenic Group Hydrolysis
1968 Science
Vervet Monkeys Vaccinated with KilledLeishmania majorParasites and Interleukin-12 Develop a Type 1 Immune Response but Are Not Protected against Challenge Infection
2001
Antigen Binding and the Immune Response II. The Large Number of Antigen-Binding Cells in Primed Animals
1970
Antibody Cytophilic for Lymphocytes
1972
Leishmaniasis vaccine candidates for development: a global overview.
2006
Antigen-Binding Cells in Normal Mouse Thymus
1970 Science
Modular Multiantigen T Cell Epitope–Enriched DNA Vaccine Against Human Leishmaniasis
2014
Increased myelopoiesis during Leishmania major infection in mice: generation of 'safe targets', a possible way to evade the effector immune mechanism.
1986
Phase 1 Study of an Inactivated Vaccine against American Tegumentary Leishmaniasis in Normal Volunteers in Brazil
1998
Antigen binding and the immune response. I. The early primary response to a protein antigen.
1970
Immunization with a Polyprotein Vaccine Consisting of the T-Cell Antigens Thiol-Specific Antioxidant,Leishmania majorStress-Inducible Protein 1, andLeishmaniaElongation Initiation Factor Protects against Leishmaniasis
2002
Generalized infection and lack of delayed hypersensitivity in BALB/c mice infected with Leishmania tropica major
1979
Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran.
2003
Characterization of T and B Antigen-Binding Cells for β-Galactosidase
1976